Abstract Background and Purpose β2‐adrenoceptor (β2AR) agonists are the cornerstone of asthma therapy and promote bronchodilation through Gαs signalling in airway smooth muscle (ASM), but their efficacy is limited by β‐arrestin‐mediated β2AR desensitization.
Sushrut D. Shah +7 more
wiley +1 more source
Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions. [PDF]
Zhang Y +5 more
europepmc +1 more source
Falcarindiol alleviates airway inflammation and oxidative stress in asthma through Nrf2 pathway activation. [PDF]
Jiang X, Lai S, Lin Z, Lai F, Wu H.
europepmc +1 more source
Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Bernardo Sousa‐Pinto +121 more
wiley +1 more source
Nonasthmatic Eosinophilic Bronchitis: An Overlooked Cause of Chronic Cough in Children. [PDF]
Al Dhouyani B, Abushahin A, Abu-Hasan M.
europepmc +1 more source
Carrageenans, widely used food additives, disrupted intestinal epithelial integrity in a gut‐on‐a‐chip model. All types (κ‐, ɩ‐, λ‐) induced cytotoxicity, inflammation and tight junction (TJ) disruption, triggering TNF‐mediated immune responses. λ‐Carrageenan had the most severe effects, supporting the Epithelial Barrier Theory linking food additives ...
Na Sun +13 more
wiley +1 more source
Inhaled anti-asthmatic therapy and tooth wear in children and adolescents: a case-control study. [PDF]
Świątkowska-Bury M +5 more
europepmc +1 more source
S100P mediates IL-13/ATF4-driven epithelial barrier dysfunction in eosinophilic asthma: a potential biomarker and therapeutic target. [PDF]
Li D +10 more
europepmc +1 more source
Emerging Paediatric Uses of Dupilumab Beyond Approvals
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese +11 more
wiley +1 more source
Lysophosphatidylcholine 18:2 exacerbates Th17-dominant inflammation in obese asthma. [PDF]
Cao L +7 more
europepmc +1 more source

